Navigation Links
SuperGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
Date:11/3/2008

DUBLIN, Calif., Nov 3 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at the New York Palace Hotel.

SuperGen's presentation at the Rodman & Renshaw 10th Annual Healthcare Conference is scheduled to begin at 11:35 a.m. EDT (8:35 a.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen, Inc.

Timothy L. Enns

SVP, Corporate Communications

& Business Development

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com

Dorland Global Public Relations

Michael Beckerich (Media)

Tel: (212) 677-7632

mbeckerich@dorland.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
2. SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007
3. SuperGen Reports 2007 Third Quarter Financial Results
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
5. SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 2016 , ... Point Source Audio® (PSA) , an ... today that the US Patent Office has approved its patent submission that covers ... design creates a lightweight and modular audio headset that has been said to ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, ... the mail from USA Medical Prescription Assistance Program. They are customized to reflect ... mailed package will include a ready-to-use, state-themed card and, in the near future, ...
(Date:4/28/2016)... ... April 28, 2016 , ... For the 10,000 Americans ... smarter about an important part of overall well-being: mental health. Now, a new book—Staying ... promote healthy aging and “cognitive vitality,” which can include everything from honing your memory ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... insurance co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy ... prescription medications from over 180 American pharmaceutical companies for $35 per month, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
Breaking Medicine Technology: